11th Sep 2020 14:09
Immupharma PLC - pharmaceutical company - Licensing partner Avion Pharmaceuticals has confirmed that while the US Food & Drug Administration review period of 45 days has now passed, its submission for a Special Protocol Assessment for its forthcoming international Phase III trial of its lupus treatment Lupuzor is still under review due to current workload of the regulatory body. Application was submitted in July.
Current stock price: 12.60 pence
Year-to-date change: down 21%
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma